Clinical trials: Heart Transplant
Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD), Solid Organ Transplant Complications
A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy
The purpose of this study is to determine the clinical benefit and characterize the safety profile of tabelecleucel for the treatment of Epstein-Barr virus-associated post-transplant lymphoproliferative disease (EBV+ PTLD) in the…
- Conditions
- Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD), Solid Organ Transplant Complications, Lymphoproliferative Disorders, Allogeneic Hematopoietic Cell Transplant
- Trial name
- ALLELE (NCT03394365)
- Testing
- tabelecleucel
- Where
- 71 sites in United States, Australia and 7 more
- Volunteers
- 115 people
- Sponsor
- Pierre Fabre Medicament
Heart Transplantation
A Study to Evaluate the Efficacy and Safety of Zenapax in Combination With CellCept, Cyclosporine, and Corticosteroids in Patients Undergoing Cardiac Transplantation
The purpose of the study is to compare the number of randomized participants in each treatment group who experience an acute rejection episode in the first 6 months after undergoing cardiac transplantation.
- Trial name
- NCT00048165
- Testing
- Daclizumab, Methylprednisolone, Mycophenolate mofetil
- Where
- 30 sites in United States, Canada and 2 more
- Volunteers
- 434 people
- Sponsor
- Hoffmann-La Roche
Heart Transplantation
Thymic Tolerance in Pediatric Heart Transplantation
The investigators hypothesize that injecting donor bone marrow cells into the recipient thymus gland at the time of heart transplantation in children will prove to be feasible and safe.
- Trial name
- NCT00151164
- Testing
- donor bone marrow cell injection into thymus gland
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Common Variable Immunodeficiency (CVID), Primary Immune Regulatory Disorder
Hematopoietic Stem Cell Transplantation (HSCT) for Common Variable Immunodeficiency (CVID) and Other Autoimmune Manifestations of Primary Immune Regulatory Disorders (PIRD)
This is a research protocol that will examine Hematopoietic Stem Cell Transplantation (HSCT) using a reduced conditioning regimen (RIC) with total body Irradiation (TBI) in those diagnosed with Common Variable Immunodeficiency…
- Conditions
- Common Variable Immunodeficiency (CVID), Primary Immune Regulatory Disorder, Immune Dysregulation, DiGeorge Syndrome
- Trial name
- CVID/PIRD (NCT07284641)
- Testing
- Hematopoietic stem cell transplant (HSCT)
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Paul Szabolcs
Coronary Artery Disease, CABG
The 10-Year Extended Follow-up of the DACAB Trial
The goal of this observational study is to learn about the very long-term effects of different antiplatelet strategies in patients who underwent coronary artery bypass grafting (CABG) and participated in the original DACAB trial.
- Conditions
- Coronary Artery Disease, CABG, Antiplatelet Therapy of Coronary Artery Bypass
- Trial name
- DACAB-FE-10Y (NCT07480629)
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Ruijin Hospital
Children Who Underwent Heart Transplantation Prior to Age 18, Received Care at Children's Healthcare of Atlanta
Allograft Fibrosis Following Pediatric Cardiac Transplantation
Transplantation is the preferred method of treating many forms of end-stage organ failure. While short-term results have improved, long-term outcomes remain inadequate.
- Trial name
- NCT00328185
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Children's Healthcare of Atlanta
Congestive Heart Failure
Assessing Changes in Myocardial Tissue and Blood in Patients With Advanced Heart Disease
Hypothesis: Tissue and serum samples collected from end-stage heart failure patients receiving left ventricular assist device implantation (LVAD) or heart transplantation will provide information regarding the basic science of…
- Trial name
- NCT01099982
- Where
- 3 sites in United States
- Volunteers
- 300 people
- Sponsor
- University of Utah
Heart Failure, Cardiac Imaging Techniques
MRI to Predict Rejection and Failure in Transplant and Cardiomyopathy Patients
Overall Research Strategy of this protocol is to refine and validate noninvasive CMR imaging sequences with invasive hemodynamic and pathology results to create a comprehensive, noninvasive, radiation-reduced regimen for…
- Conditions
- Heart Failure, Cardiac Imaging Techniques, Congenital Heart Defects
- Trial name
- NCT03822442
- Where
- United States
- Volunteers
- 113 people
- Sponsor
- Children's National Research Institute
Orthotopic Heart Transplantation, Graft Failure
Terminal Graft Failure
One of the risks associated with heart transplantation is failure of the graft. A graft is where the new heart is attached to the original vessels in the body.
- Trial name
- NCT00208884
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Emory University
DiGeorge Anomaly, Complete DiGeorge Anomaly
Phase I/II Thymus Transplantation With Immunosuppression #950
The study purpose is to determine if cultured thymus tissue implantation (CTTI) (previously described as transplantation) with tailored immunosuppression based on the recipient's pre-implantation T cell population is a safe and…
- Conditions
- DiGeorge Anomaly, Complete DiGeorge Anomaly, Complete Atypical DiGeorge Anomaly, Complete DiGeorge Syndrome
- Trial name
- #950 (NCT00579527)
- Testing
- Cultured Thymus Tissue for Implantation (CTTI), Cultured Thymus Tissue Implantation and Parental Parathyroid Transplantation, Blood Draw
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Sumitomo Pharma Switzerland GmbH
Heart Transplantation
Urinary Proteomics in Predicting Heart Transplantation Outcomes
uPROPHET aims to validate urinary proteomics for risk stratification and monitoring graft performance is recipients of heart transplants
- Trial name
- uPROPHET (NCT03152422)
- Testing
- Urinary proteomics
- Volunteers
- 352 people
- Sponsor
- KU Leuven
Aortic Valve Disease, Coronary Artery Disease
Early Outcomes of Concomitant Transcatheter Aortic Valve Implantation and Off-pump Coronary Artery Bypass Grafting in Management of Severe Symptomatic Aortic Stenosis and Coronary Artery Disease
Study Objectives/Specific Aims Overall Goal: To study the outcomes of patients undergoing TAVI, their subsequent results and complications.
- Trial name
- NCT04525339
- Testing
- TAVI and Off pump CABG
- Where
- Egypt
- Volunteers
- 15 people
- Sponsor
- Assiut University
DiGeorge Syndrome, DiGeorge Anomaly
Thymus Transplantation With Immunosuppression
The research purpose is to determine if thymus transplantation with immunosuppression is a safe and effective treatment for complete DiGeorge anomaly.
- Conditions
- DiGeorge Syndrome, DiGeorge Anomaly, Complete DiGeorge Anomaly, Complete DiGeorge Syndrome
- Trial name
- 884 (NCT00579709)
- Testing
- Thymus Tissue for Transplantation
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Sumitomo Pharma Switzerland GmbH
Heart Failure
Coronary Artery Disease in Hearts Donated for Transplantation
In spite of recent initiatives, in particular, the introduction into clinical practice of donation after circulatory death (DCD), there is a persistent mismatch between the demand for donor hearts for transplantation and their…
- Trial name
- NCT06528834
- Where
- United Kingdom
- Volunteers
- 10 people
- Sponsor
- Royal Brompton & Harefield NHS Foundation Trust
Heart Transplant
Registry for Longitudinal Evaluation of Heart Transplanted Patients
The overall objective of compiling this registry is to obtain a complete collection of data, in a dedicated database, on all patients who have undergone transplantation at our Center in order to assess the main causes of…
- Trial name
- NCT07431814
- Where
- Italy
- Volunteers
- 60 people
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
CABG, Revascularization
Is Total Arterial Revascularization Superior to Multiarterial Grafting in Coronary Artery Bypass Grafting
Retrospective study of adult patients with multivessel disease undergoing isolated coronary artery bypass grafting (CABG) in three centers between January 1st, 2009, and December 31st, 2023.
- Trial name
- NCT06766084
- Testing
- CABG
- Volunteers
- 7,878 people
- Sponsor
- Technion, Israel Institute of Technology
CABG, Ethnic Group
Outcomes of Coronary Artery Bypass Grafting in Israeli Jews and Arabs
Retrospective study of adult patients with multivessel disease undergoing isolated CABG in three centers between January 1st, 2009, and December 31st, 2023.
- Trial name
- NCT06766123
- Testing
- CABG
- Volunteers
- 7,067 people
- Sponsor
- Technion, Israel Institute of Technology
Psychiatric Diagnosis, Cognition Disorders
Mood and Cognitive Outcome After Heart Transplantation (the MOODHEART Study)
The investigators aim at characterizing neuropsychiatric consequences of heart transplantation (HTX) and at assessing the impact of depressive symptoms after HTX on mortality and cardiac allograft vasculopathy (CAV).
- Trial name
- NCT02035865
- Where
- Norway
- Volunteers
- 74 people
- Sponsor
- Oslo University Hospital
Heart Transplantation, Kidney Transplantation
A Study to Compare How the Body Absorbs and Processes Two Different Formulations of the Anti-rejection Medication Tacrolimus (Advagraf® or Prograf®) in Children Receiving an Organ Transplant, and How Safe and Effective They Are Over a Longer Period of Time
The purpose of this study is to compare how the body absorbs and processes two different formulations of the anti-rejection medication tacrolimus (Advagraf® or Prograf®) in children receiving an organ transplant, and how safe and…
- Conditions
- Heart Transplantation, Kidney Transplantation, Liver Transplantation
- Trial name
- NCT01614665
- Testing
- Tacrolimus, Tacrolimus prolonged release
- Where
- 10 sites in Czechia, France and 3 more
- Volunteers
- 44 people
- Sponsor
- Astellas Pharma Europe Ltd.
Cardiac Allograft Vasculopathy
Angiotensin Converting Enzyme (ACE) Inhibition and Cardiac Allograft Vasculopathy
Cardiac transplantation is the ultimate treatment option for patients with end stage heart failure. Cardiac allograft vasculopathy remains a leading cause of morbidity and mortality after transplantation.
- Trial name
- NCT01078363
- Testing
- ramipril
- Where
- 2 sites in United States
- Volunteers
- 96 people
- Sponsor
- Stanford University